Cholera Vaccine Use Is Associated With a Reduced Risk of Death in Patients With Colorectal Cancer: A Population-Based Study

Ji, Jianguang; Sundquist, Jan; Sundquist, Kristina

doi:10.1053/j.gastro.2017.09.009

Cited by 25 publications

(32 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We used the Swedish Prescribed Drug Register to evaluate multiple use of medications occurring among the entire Swedish population from 2006 to 2014. This register was created on 1st July 2005 and includes data on all prescribed drugs dispensed at pharmacies in Sweden (Ji et al, 2018;Huang et al, 2019). The rate of missing patient identity data is estimated to be lower than 0.3% (Wettermark et al, 2007).…”

Section: Study Populationmentioning

confidence: 99%

An Increasing Trend in the Prevalence of Polypharmacy in Sweden: A Nationwide Register-Based Study

Zhang

Sundquist

et al. 2020

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Polypharmacy is becoming a global health problem. The aims of this study were to evaluate the temporal trends in the prevalence of polypharmacy in Sweden and to explore polypharmacy disparities by age, gender, education, and immigration status. Methods: Polypharmacy and excessive polypharmacy were evaluated using data extracted from the Swedish Prescribed Drug Register between 2006 and 2014. Polypharmacy was defined as being exposed to five or more drugs and excessive polypharmacy was defined as being exposed to 10 or more drugs during 1 month respectively. Average annual percent change (AAPC) was calculated using Joinpoint Statistical Software. Results: The prevalence of polypharmacy increased from 16.9% in 2006 to 19.0% in 2014 with an AAPC of 1.3; the prevalence of excess polypharmacy increased from 3.8% in 2006 to 5.1% in 2014 with an AAPC of 3.4. The prevalence of polypharmacy and excessive polypharmacy increased dramatically with age and peaked up to 79.6% and 36.4% in individuals aged 90 and above respectively. Females and individuals with lower education level were associated with a higher rate of polypharmacy and excessive polypharmacy. Immigrants from Middle-Eastern countries had the highest rate of polypharmacy and excessive polypharmacy, whereas individuals from Western Europe countries had the lowest rate. Conclusion: The prevalence of polypharmacy has increased gradually in Sweden during the past decade. Individuals with older age, female sex, or lower education have a higher rate of polypharmacy and excessive polypharmacy. Immigrants from Middle-Eastern countries showed a higher rate of polypharmacy.

show abstract

Section: Study Populationmentioning

confidence: 99%

An Increasing Trend in the Prevalence of Polypharmacy in Sweden: A Nationwide Register-Based Study

Zhang

Sundquist

et al. 2020

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Of considerable interest may be population-based studies investigating potential association between the Dukoral ® vaccine and gastrointestinal disorders involving mucosal inflammation. In a very recent study of patients who were diagnosed with colorectal cancer from July 2005 through December 2012 in Sweden, it was revealed that those who had previously received Dukoral ® had a significantly reduced risk of death from colorectal cancer (CRC) [ 89 ]. Although the underlying mechanism is not clear at this point, the authors speculated that CTB might be associated with a risk reduction of CRC [ 89 ].…”

Section: Conclusion—challenges For the Use Of Ctb As An Immunomodmentioning

confidence: 99%

“…In a very recent study of patients who were diagnosed with colorectal cancer from July 2005 through December 2012 in Sweden, it was revealed that those who had previously received Dukoral ® had a significantly reduced risk of death from colorectal cancer (CRC) [ 89 ]. Although the underlying mechanism is not clear at this point, the authors speculated that CTB might be associated with a risk reduction of CRC [ 89 ]. This observation warrants a comprehensive investigation on this subject.…”

Section: Conclusion—challenges For the Use Of Ctb As An Immunomodmentioning

confidence: 99%

Therapeutic Potential of Cholera Toxin B Subunit for the Treatment of Inflammatory Diseases of the Mucosa

Royal

Matoba

2017

Toxins

View full text Add to dashboard Cite

Cholera toxin B subunit (CTB) is a mucosal immunomodulatory protein that induces robust mucosal and systemic antibody responses. This well-known biological activity has been exploited in cholera prevention (as a component of Dukoral® vaccine) and vaccine development for decades. On the other hand, several studies have investigated CTB’s immunotherapeutic potential in the treatment of inflammatory diseases such as Crohn’s disease and asthma. Furthermore, we recently found that a variant of CTB could induce colon epithelial wound healing in mouse colitis models. This review summarizes the possible mechanisms behind CTB’s anti-inflammatory activity and discuss how the protein could impact mucosal inflammatory disease treatment.

show abstract

“…Cholera vaccine might be repositioned (drug repurposing) and might be used as adjuvant therapy in patients with prostate cancer. Our previous study found that post-diagnostic use of cholera vaccine (including killed Vibrio cholerae O1 whole cells and recombinant CTB) can improve the prognosis in patients with colorectal cancer, which suggests that cholera toxin might have an antineoplastic effect 7 – 13 . In this study, we aimed to explore whether post-diagnostic use of cholera vaccine might be associated with a reduced mortality rate in patients diagnosed with prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients

Sundquist

2018

Nat Commun

Self Cite

View full text Add to dashboard Cite

Recent evidence suggests that cholera toxin might have multiple functions regarding the ability to regulate the immune system. However, it is unknown whether subsequent administration of cholera vaccine might affect the mortality rate in patients with prostate cancer. Here we report that patients in Sweden, who were diagnosed with prostate cancer between July 2005 and December 2014 and used cholera vaccine, have a decreased risk of death from prostate cancer (HR, 0.57; 95% CI, 0.40–0.82) as compared to patients with prostate cancer but without cholera vaccine use, adjusted for a range of confounding factors. In addition, patients using cholera vaccine show a decreased risk of death overall (HR, 0.53; 95% CI, 0.41–0.69). The decreased mortality rate is largely consistent, irrespective of patients’ age or tumor stage at diagnosis. In this population-based study, we suggest that subsequent administration of cholera vaccine after prostate cancer diagnosis might reduce the mortality rate.

show abstract

Cholera Vaccine Use Is Associated With a Reduced Risk of Death in Patients With Colorectal Cancer: A Population-Based Study

Cited by 25 publications

References 35 publications

An Increasing Trend in the Prevalence of Polypharmacy in Sweden: A Nationwide Register-Based Study

An Increasing Trend in the Prevalence of Polypharmacy in Sweden: A Nationwide Register-Based Study

Therapeutic Potential of Cholera Toxin B Subunit for the Treatment of Inflammatory Diseases of the Mucosa

Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients

Contact Info

Product

Resources

About